Washington, District of Columbia, United States
Contact Info
718 followers
500+ connections
About
Activity
-
Director William Milliken spoke to MLex on the recent Supreme Court ruling in SEC v. Jarkesy, commenting that the Seventh Amendment analyses applied…
Director William Milliken spoke to MLex on the recent Supreme Court ruling in SEC v. Jarkesy, commenting that the Seventh Amendment analyses applied…
Liked by David Holman
-
🎉 Sterne Kessler shines once again in Vault's 2025 rankings! Recognized as one of the "Best Midsize Law Firms to Work For," we've earned top…
🎉 Sterne Kessler shines once again in Vault's 2025 rankings! Recognized as one of the "Best Midsize Law Firms to Work For," we've earned top…
Shared by David Holman
Experience & Education
Publications
-
The New USPTO Examiner Manual And 102(e) Prior Art
Law360
Recent Federal Circuit decisions have held that, for a published patent application to qualify as §102(e) prior art as of its provisional application filing date, the provisional application must (1) support the relied upon disclosures in the published application and (2) provide §112, first paragraph, support for the claims in the published application. Consistent with the Federal Circuit precedent, the Patent Trial and Appeal Board has applied this §102(e) analysis to both patents and…
Recent Federal Circuit decisions have held that, for a published patent application to qualify as §102(e) prior art as of its provisional application filing date, the provisional application must (1) support the relied upon disclosures in the published application and (2) provide §112, first paragraph, support for the claims in the published application. Consistent with the Federal Circuit precedent, the Patent Trial and Appeal Board has applied this §102(e) analysis to both patents and published patent applications. The U.S. Patent and Trademark Office’s January 2018 updates to the Manual of Patent Examining Procedure, however, seem to provide guidance for examiners that is at odds with the Federal Circuit and PTAB precedent. This article discusses the history of the Wertheim doctrine, Dynamic Drinkware and other recent Federal Circuit decisions, how §102(e) prior art has been treated at the PTAB, and as-yet unanswered questions involving the Wertheim doctrine.
-
Patent Office Litigation, Second Edition
Thomson Reuters
Authored by nearly 70 Sterne Kessler attorneys, who have handled over 600 of the nearly 6,000 proceedings before the Patent Trial and Appeal Board (PTAB). The treatise provides readers with fresh and comprehensive explorations of all aspects of contested patent proceedings before the US Patent & Trademark Office (USPTO), and the interplay with the Administrative Procedures Act (APA), US District Courts, US International Trade Commission (USITC), US Court of Appeals for the Federal Circuit…
Authored by nearly 70 Sterne Kessler attorneys, who have handled over 600 of the nearly 6,000 proceedings before the Patent Trial and Appeal Board (PTAB). The treatise provides readers with fresh and comprehensive explorations of all aspects of contested patent proceedings before the US Patent & Trademark Office (USPTO), and the interplay with the Administrative Procedures Act (APA), US District Courts, US International Trade Commission (USITC), US Court of Appeals for the Federal Circuit (Federal Circuit), complex patent preparation and prosecution strategies before the USPTO, and patent enforcement in other jurisdictions, such as the European Union and the proposed Unified Patent Court.
-
Inter Partes Reviews: The Effect of Estoppel
World Intellectual Property Review
Now that the inter partes review system is three years old, what effects have the estoppel provisions had on concurrent or subsequent district court litigation?
-
Human Embryonic Stem Cell Research: Statutory Interpretation of the Dickey-Wicker Amendment and the Future of Biomedical Research
Federal Courts Law Review
2011 Fed. Cts. L. Rev. 4 (Student Works Issue)
-
Protection of nonhuman primates against two species of Ebola virus infection with a single complex adenovirus vector
Clinical and Vaccine Immunology, Apr;17(4):572-81
Other authors -
-
A Complex Adenovirus Vectored Vaccine Against Rift Valley Fever Virus Protects Mice Against Lethal Infection in the Presence of Pre-existing Vector Immunity
Clinical and Vaccine Immunology, Nov;16(11):1624-32
Other authors -
-
A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Protects Monkeys Against All Four Serotypes of Dengue Viruses
Journal of Virology, Jul;82(14):6927-34
Other authors -
-
Acid ceramidase inhibition: a novel target for cancer therapy
Frontiers in Bioscience, Jan 1;13:2293-8
Additional authors: YA Hannun YA, S Rubinchik, Z Szulc, TE Keane, M Tavassoli, JS Norris JS.
Other authors -
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells
Cancer Chemotherapy and Pharmacology, Feb;61(2):231-42
Additional author: JS Norris
Other authors -
-
Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses
Vaccine, May 19;26(21):2627-39
Other authors -
-
Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections
Clinical and Vaccine Immunology, Mar;15(3):460-7
Other authors -
-
Complex Adenovirus-mediated expression of C, PreM, E, and NS1 proteins of West Nile Virus induces both humoral and cellular immune responses
Clinical and Vaccine Immunology, Sep;14(9):1117-26
Other authors -
-
Expression of dengue virus type 1 and type 2 antigens from a single adenoviral vector induces bivalent humoral immune responses
American Journal of Tropical Medicine and Hygiene, April 1;76(4): 743-51.
Other authors -
-
Role of Acid Ceramidase in Resistance to FasL: Therapeutic Approaches Based on Acid Ceramidase Inhibitors and FasL Gene Therapy
Molecular Therapy, Jul;15(7):1259-63
Additional authors: Dong JY, Bielawska A, Hannun YA, Norris JS.
Other authors -
-
Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes
Clinical and Vaccine Immunology, 14(2):182-9
Other authors -
-
Combined Therapeutic Use of AdGFPFasL and Small Molecule Inhibitors of Ceramide Metabolism in Prostate and Head and Neck Cancers: A Status Report
Cancer Gene Therapy, Dec;13(12):1045-51
Additional authors: Norris K, L. Obeid, Rubinchik S, Tavassoli M, Tomlinson S, Dong J, Voelkel-Johnson C, Liu X.
Other authors -
-
De Novo Syntheses Of Marburg Virus Antigens From Adenovirus Vectors Induce Potent Humoral And Cellular Immune Responses
Vaccine, 24(15):2975-2986
Additional authors: Swain BM, Hart MK, Pratt WD, Dong JY.
Other authors -
-
FasL Gene Therapy: A New Therapeutic Modality for Head and Neck Cancer
Cancer Gene Therapy, Aug;13(8):739-45
Other authors -
-
Involvement of sphingolipids in apoptin-induced cell killing
Molecular Therapy, Nov;14(5):627-36
Additional authors: Keane TE, Tavassoli M, Hannun YA, Norris JS.
Other authors -
-
Modulation of Ceramide Metabolism Enhances Viral Protein Apoptin's Cytotoxicity in Prostate Cancer.
Molecular Therapy, Nov;14(5):637-46
Additional authors: Tavassoli M, Norris JS
Other authors -
-
New insights on the use of desipramine as an inhibitor for acid ceramidase
FEBS Letters, Aug 21;580(19):4751-6
Other authors -
-
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck
Future Oncology, 1(1):116-123
Other authors -
-
In vitro efficacy of Fas Ligand gene therapy for the treatment of bladder cancer
Cancer Gene Therapy, 12(1):12-18
Other authors -
-
Inter partes reviews: the effect of estoppel
World Intellectual Property Review, Dec. 2015
Now that the inter partes review system is three years old, what effects have the estoppel provisions had on concurrent or subsequent district court litigation?
Other authors -
Patents
-
Ceramides and apoptosis-signaling ligand
Issued US 8,592,419
The invention provides the compounds of formula (): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, A, X, Y, a, b and n are as defined herein. Also disclosed are methods for making the compounds of formula (I) and their use in treating or preventing diseases associated with cell overproliferation and dysfunctional sphingolipid signal transduction. The invention also encompasses the use of the compounds in combination with an apoptosis-signaling ligand, such as Fas ligand.…
The invention provides the compounds of formula (): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, A, X, Y, a, b and n are as defined herein. Also disclosed are methods for making the compounds of formula (I) and their use in treating or preventing diseases associated with cell overproliferation and dysfunctional sphingolipid signal transduction. The invention also encompasses the use of the compounds in combination with an apoptosis-signaling ligand, such as Fas ligand. Preferably, the Fas ligand is administered in the form of a gene therapy agent.
Other inventors -
More activity by David
-
Congratulations to #MTCMember QIAGEN for their major expansion in Frederick County, Maryland! This exciting growth not only strengthens our local…
Congratulations to #MTCMember QIAGEN for their major expansion in Frederick County, Maryland! This exciting growth not only strengthens our local…
Liked by David Holman
-
When I do travel to DC, it's great to be able work in such a dynamic and innovative space - read more about Sterne Kessler's new office on K Street…
When I do travel to DC, it's great to be able work in such a dynamic and innovative space - read more about Sterne Kessler's new office on K Street…
Liked by David Holman
-
Proud that NextNav has been selected to participate in this next step in providing Complementary and Resilent GPS type network. Congrats to our…
Proud that NextNav has been selected to participate in this next step in providing Complementary and Resilent GPS type network. Congrats to our…
Liked by David Holman
-
Thankful for my brilliant and supportive colleagues at Sterne, Kessler, Goldstein & Fox! #patentlaw #supportivefirmculture #skgf
Thankful for my brilliant and supportive colleagues at Sterne, Kessler, Goldstein & Fox! #patentlaw #supportivefirmculture #skgf
Liked by David Holman
-
JUST IN: CNBC ranked Virginia as the nation’s top state for business in 2024! Thank you to Governor Glenn Youngkin for his continued leadership and…
JUST IN: CNBC ranked Virginia as the nation’s top state for business in 2024! Thank you to Governor Glenn Youngkin for his continued leadership and…
Liked by David Holman
-
We’re pleased to announce that five Sterne Kessler attorneys have been ranked in the 2024 edition of WIPR Leaders, published by WIPR - World IP…
We’re pleased to announce that five Sterne Kessler attorneys have been ranked in the 2024 edition of WIPR Leaders, published by WIPR - World IP…
Shared by David Holman
-
🌍✨ Managing IP spoke with patent lawyers in the U.S. and Europe on top trends from the first half of 2024, including: 1️⃣ Unified Patent Court…
🌍✨ Managing IP spoke with patent lawyers in the U.S. and Europe on top trends from the first half of 2024, including: 1️⃣ Unified Patent Court…
Shared by David Holman
People also viewed
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore MoreOthers named David Holman in United States
254 others named David Holman in United States are on LinkedIn
See others named David Holman